Cargando…
On the Regulatory Approval Pathway of Biosimilar Products
Biosimilars (or follow-on biologics) are a new class of medicine which enters the market subsequent to a previously approved version. They have demonstrated similarity to innovator biologic products in terms of quality, safety, and efficacy. The EMA has taken the lead in the regulatory approval fram...
Autores principales: | Wang, Jun, Chow, Shein-Chung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763644/ https://www.ncbi.nlm.nih.gov/pubmed/24281406 http://dx.doi.org/10.3390/ph5040353 |
Ejemplares similares
-
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015) -
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020) -
Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval
por: Strauss, David G., et al.
Publicado: (2022) -
Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities
por: Ingram, Beverly, et al.
Publicado: (2021) -
A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar
por: Reinisch, Walter, et al.
Publicado: (2021)